Zoetis Inc
Latest Zoetis Inc News and Updates
How Merial Contributes to Sanofi’s Growth
Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.
Zoetis: An attractive business model
Zoetis said in a recent statement that “its unique characteristics have established the company as the world leader in animal health, growing revenue faster than the market for the last three years.”
Must-know trends that drive Zoetis’ growth
Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.
Why Zoetis’s Apoquel and Cytopoint Are Expected to Report Robust Revenues
In 1Q17, Zoetis’s (ZTS) dermatology portfolio reported revenues of ~$57 million, driven by the steady adoption of Cytopoint and Apoquel.
Why Zoetis Expects to See Robust Revenue Growth in 2017
Zoetis (ZTS) has adopted a targeted R&D strategy that has resulted in multiple new product launches.
Performance of Eli Lilly & Co.’s Elanco in 1Q17
Eli Lilly & Co.’s (LLY) Animal Health company, Elanco, reported an increase of 2% in revenues to $769.4 million in 1Q17, compared to $754.6 million in 1Q16.
Mylan’s Business Model: A Key Investor Rundown
In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.
A Key Look at Abbott Laboratories’ Acquisitions and Divestments
Inorganic growth through acquisitions has led to the expansion of Abbott Laboratories across geographies and to the broadening of its product portfolio.
